ESR1 and breast cancer: It was found that SDC4 overexpression is a poor prognostic factor in patients with ER-negative and ER-/PR-negative breast cancer, whereas it is a good prognostic factor for all breast cancer patients analyzed, irrespective of the molecular subtypes.